天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

返回ChemicalBook首頁>CAS數(shù)據(jù)庫列表>143748-18-9

143748-18-9

中文名稱 PACAP (6-38), HUMAN, OVINE, RAT
英文名稱 PACAP 6-38
CAS 143748-18-9
分子式 C182H300N56O45S
分子量 4024.74
MOL 文件 143748-18-9.mol
更新日期 2024/12/16 11:45:49
143748-18-9 結(jié)構(gòu)式 143748-18-9 結(jié)構(gòu)式

基本信息

中文別名
HUMAN PACAP(6-38)
英文別名
PACAP 6-38
PACAP-38 (6-38)
HumanPACAP(6-38)
PACAP (6-38), HUMAN, OVINE, RAT
PACAP (6-38) (HUMAN, SHEEP, RAT)
PACAP (HUMAN, 6-38) (OVINE, RAT)
FTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2
PACAP (6-38), AMIDE, HUMAN, OVINE, RAT
PACAP-38 (6-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT)
PITUITARY ADENYLATE ACTIVATING POLYPEPTIDE (6-38) (HUMAN, OVINE, RAT)

物理化學(xué)性質(zhì)

儲存條件-15°C
溶解度H2OPeptide Solubility and Storage Guidelines:1.??Calculate the length of the peptide.2.??Calculate the overall charge of the entire peptide according to the following table:3.??Recommended solution:
形態(tài)固體
水溶解性Soluble to 2 mg/ml in water

常見問題列表

生物活性
PACAP (6-38), human, ovine, rat 是一種有效的 PACAP 受體拮抗劑。PACAP (6-38) 作用于 PACAP I 型受體,PACAP II 型受體 VIP1 和 PACAP II 型受體 VIP2,IC50 分別為 30 nM,600 nM 和 40 nM。
靶點(diǎn)

IC50: 30 nM (PACAP type I receptor), 600 nM (PACAP type II receptor VIP 1 ), 40 nM (PACAP type II receptor VIP 2 )

體外研究

An increase of dopamine (DA) content by HPLC analysis and/or cell proliferation identified by MTT assay by Dexamethasone (DEX) is also observed which can be inhibited by PACAP (6-38) at concentration sufficient to block PACAP type 1 (PAC1) receptor. Pretreatment with PAC1 receptor antagonist PACAP (6-38) at 0.1 or 1 μM for 2 h significantly blocks this increase of DA content by 1 μM DEX. The MTT assay shows that DEX increases cell proliferation. Moreover, this action is also inhibited by the pre-incubation of PACAP (6-38). PACAP (6-38) at 1μM shows no effect on DA content and cell proliferation for 24 h. However, PACAP (6-38) at 0.3 μM has been mentioned to reduce the spontaneous tyrosine hydroxylase (TH) accumulation in differentiated retinal cultured cells for 5 days.

體內(nèi)研究

Intravesical administration of the PAC1 receptor antagonist, PACAP (6-38) (300 nM), significantly (p≤0.01) increases intercontraction interval (2.0-fold) and void volume (2.5-fold) in NGF-OE mice. Intravesical instillation of PACAP (6-38) also decreases baseline bladder pressure in NGF-OE mice. Intravesical administration of PACAP (6-38) (300 nM) significantly (p≤0.01) reduces pelvic sensitivity in NGF-OE mice but is without effect in WT mice.

"143748-18-9" 相關(guān)產(chǎn)品信息
127317-03-7 137061-48-4 132769-35-8 138764-85-9 144025-82-1 160489-86-1 124123-15-5 36635-61-7 2769-64-4 645-96-5 7188-38-7 14542-93-9 2999-46-4 39687-95-1